Nov 25- Allergan PLC said on Wednesday it will not appeal to the U.S. Supreme Court a court ruling this year that blocked the company from discontinuing its top-selling Alzheimer's drug in favor of a pricier version. Allergan will also pay $172,000 in legal expenses under a settlement with New York Attorney General Eric Schneiderman, who filed an antitrust...» Read More
"I think in particular, the 'individual mandate', had it been framed as a tax, it would have been on much more solid ground, just as the Medicare tax is," says Ronald Williams, former Aetna chairman and CEO, weighing in on the pending Supreme Court decision on health care reform.
"There's great hatred in politics like I've never seen before," says Donald Trump, Trump Organization chairman & president, discussing the political headwinds facing legislation to simplify tax reform and reduce the nation's huge deficits. Trump also weighs in on the Supreme Court's decision on immigration, with Stephen Schwarzman, BlackStone Group chairman & CEO.
There's clearly a consensus in the House that Obamacare was a mistake and we need to repeal the law, says Rep. Eric Cantor, (R-VA), discussing the pending Supreme Court decision on health care; and addressing the "serious" deficit problem facing the nation and the best way to create jobs.
Will the Supreme Court rule against the Affordable Care Act? Ben White, POLITICO Wall Street correspondent, weighs in on the political implications of the high court's ruling.
The Supreme Court has reaffirmed its 2-year-old decision allowing corporations to spend freely to influence elections and has backed Arizona police checks of immigration status.
The Supreme Court is expected to hand down its decision on President Obama's health care law this week, with CNBC's Bertha Coombs. Dave Shove, BMO Capital Markets, and Alex Morozov, Morningstar, weigh in.
CNBC's Hampton Pearson reports the Supreme Court upholds some parts of the controversial immigration law, and rejects others.
A preview of the U.S. markets ahead of the open, with CNBC's Kelly Evans, including a look at a possible verdict today from the Supreme Court on President Obama's health care law.
The White House is preparing contingency plans if the Supreme Court declares part of President Obama's signature health care reform unconstitutional, The New York Times reports.
How the “Mad Money” host recommends investors position themselves regardless of how the high court rules on health care reform.
Mad Money host Jim Cramer looks ahead to next week's major economic data, and suspects the markets would see a sharp sell-off if the Supreme Court rules in favor of Obamacare.
At this very moment, the economic basis of the entire health-care system is up in the air, as a result of the imminent U.S. Supreme Court opinion in the health care reform law cases. Court observers expect the decision any day now, and most likely before the end of June.
"More importantly, Europe and the emerging markets are worse," says Jack Welch, former GE chairman & CEO, sharing his thoughts on the state of the global economy, and the impact of regulations on economic recovery.
One of the biggest misconceptions about President Obama's health care overhaul isn't who the law will cover, but rather who it won't. If it survives Supreme Court scrutiny, an estimated 26 million Americans will remain without coverage.
Should the U.S. Supreme Court strike down health care reform, here’s how Cramer recommends playing it.
Toby Cosgrove, Cleveland Clinic CEO & president, discusses the state of the U.S. health care system and weighs in on the future of President Obama's health reform law.
Dr. Gary Gottlieb, Partners HealthCare president and CEO, discusses why he is giving President Obama's Health Care Reform law good grades, ahead of a pending Supreme Court decision on the legislation.
A look at the winner and losing stock trades, if the Supreme Court overturns President Obama's health insurance reform law, with Gary Brode, Silver Arrow Investment Management.
If the Supreme Court shoots down Obamacare, what does that mean for big pharma? Deutsche Bank analyst Barbara Ryan weighs in.
Barbara Ryan, Deutsche Bank Securities senior pharmaceutical analyst, takes a look at the vital signs of big drug companies and weighs in on what to expect from the Supreme Court's ruling on President Obama's health care overhaul plan.